CPRX
Catalyst Pharmaceuticals Inc

15,805
Mkt Cap
$2.84B
Volume
1.37M
52W High
$26.58
52W Low
$19.05
PE Ratio
13.29
CPRX Fundamentals
Price
$22.78
Prev Close
$23.10
Open
$23.08
50D MA
$20.63
Beta
0.98
Avg. Volume
1.3M
EPS (Annual)
$1.31
P/B
3.05
Rev/Employee
$2.72M
Loading...
Loading...
News
all
press releases
Catalyst Pharmaceuticals (NASDAQ:CPRX) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS
Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the consensus...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Citigroup Increases Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $33.00
Citigroup raised their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday...
MarketBeat·5d ago
News Placeholder
Catalyst Pharmaceuticals (NASDAQ:CPRX) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·5d ago
News Placeholder
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
Zacks·7d ago
News Placeholder
Compared to Estimates, Catalyst (CPRX) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·7d ago
News Placeholder
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +33.33% and +8.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·14d ago
News Placeholder
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·15d ago
News Placeholder
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·20d ago
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·1mo ago

Latest CPRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.